LeMaitre Vascular, Inc.
LMATLeMaitre Vascular, Inc. is a medical device company specializing in the development, manufacture, and commercialization of surgical solutions for peripheral vascular and cardiac use. Established to address the needs of vascular surgeons, the company offers a broad portfolio of products including vascular grafts, angioplasty balloons, stents, and other devices used in minimally invasive surgical procedures. LeMaitre Vascular serves a global customer base with an emphasis on improving patient outcomes through innovative technology.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 4, 2026 | $0.25 | 2026-05-21 | 2026-05-21 |
| March 26, 2026 | $0.25 | 2026-03-12 | 2026-03-12 |
| December 4, 2025 | $0.20 | 2025-11-20 | 2025-11-20 |
| September 4, 2025 | $0.20 | 2025-08-21 | 2025-08-21 |
| May 29, 2025 | $0.20 | 2025-05-15 | 2025-05-15 |
Dividends Summary
- Consistent Payer: LeMaitre Vascular, Inc. has rewarded shareholders with 62 dividend payments over the past 15 years.
- Total Returned Value: Investors who held LMAT shares during this period received a total of $5.44 per share in dividend income.
- Latest Payout: The most recent dividend of $0.25/share was paid 44 days ago, on June 4, 2026.
- Yield & Schedule: LMAT currently pays dividends quarterly with an annual yield of 0.89%.
- Dividend Growth: Since 2011, the dividend payout has grown by 1150.0%, from $0.02 to $0.25.
- Dividend Reliability: LMAT has maintained or increased its dividend for 62 consecutive payments.
Company News
LeMaitre Vascular reported Q1 2026 sales of $66.6mm (+11% organic growth) with gross margin expanding 350 bps to 72.7% and EPS growing 42% to $0.68. The company raised full-year 2026 guidance to $280mm sales (+12%) and $3.00 EPS (+26% adjusted). Strong performance was driven by Artegraft growth of 36%, geographic expansion, and operating leverage...
LeMaitre Vascular's Senior VP of Operations sold $285,000 in stock (2,625 shares) on March 11, 2026, representing 28.22% of his direct holdings. The sale appears to be a routine option-driven liquidity event rather than a red flag, as the company reported strong Q4 results with 16% sales growth, 47% operating income increase, raised its dividend ...
LeMaitre Vascular announced its participation in five investor conferences scheduled for March 2026, including presentations at the Leerink Partners Global Healthcare Conference, Citizens Life Sciences Conference, and KeyBanc Capital Markets Healthcare Forum, as well as 1x1 meetings at the Barclays Annual Global Healthcare Conference and ROTH Con...
LeMaitre Vascular will release its third quarter 2025 financial results on November 6, 2025, after market close, with a conference call scheduled for 5:00 PM EST to discuss results and company outlook.
LeMaitre Vascular reported strong Q2 2025 financial results, with GAAP revenue of $64.2 million, exceeding estimates and growing 15% year-over-year. The company saw significant growth in catheters and grafts, expanded gross margins to 70%, and raised full-year guidance.
